큰 망막색소상피 박리를 동반한 맥락막혈관신생에서의 복합치료 = Combination Treatment for Choroidal Neovascularization Associated With Large Retinal Pigment Epithelial Detachment

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate the efficacy of the combination therapy of intravitreal bevacizumab injection and photodynamic therapy
in neovascular age-related macular degeneration associated with large retinal pigment epithelial detachment.
Methods: A total of 13 eyes were reviewed, with 9 eyes diagnosed with definite choroidal neovascularization (CNV) and 4 eyes
diagnosed with CNV or polypoidal choroidal vasculopathy (PCV) becausethe exact type could not be determined. Photodynamic
therapy was performed within 1 week after bevacizumab injection according to indocyanine green angiography (ICGA). Additional
bevacizumab injections were performed within a 4 to 6 week interval. Additional photodynamic therapy was performed within
4 months.
Results: The visual acuity on final examination had improved in 3 eyes (23.1%), was maintained in 7 eyes (53.8%), and decreased
in 3 eyes (23.1%). The change of the PED before and after treatment showed regression in 5 eyes (38.5%), recurrence after
regression in 2 eyes (15.4%), persistence in 4 eyes (30.8%), and retinal pigment epithelial tear in 2 eyes (15.4%). The maintained
or improved visual acuity rate was 66.7% (6/9) and 100% (4/4) in the CNV and CNV or PCV group, respectively.
Conclusions: The combination therapy in neovascular age-related macular degenerationassociated with large retinal pigment
epithelial detachment is a viable alternative treatment in the stabilization and improvement of vision. However, further studies with
long-term follow up and controlled studies with anti-vascular endothelial growth factor antibody monotherapy are required.

국문 초록 (Abstract)

목적: 큰 망막색소상피박리(PED)를 동반한 신생혈관 나이관련황반변성에서 유리체강내 bevacizumab 주사와 광역학요법(PDT)의 복
합치료 효과를 알아보았다.
대상과 방법: 맥락막혈관신생으로 진단된 9안, 맥락막혈관신생과 결절맥락막혈관병증 사이에 진단이 모호한 4안, 총 13안을 대상으로
하였다. Bevacizumab 주사 후 1주일 이내에 인도시아닌형광안저혈관조영에 따른 PDT를 시행하였다. 추가적인 주사는 4~6주, 추가적인
PDT는 늦어도 4개월 간격으로 시행하였다.
결과: 최종 검사 때 시력변화는 호전 3안(23.1%), 유지 7안(53.8%), 악화 3안(23.1%)이었다. PED의 변화는 소실 5안(38.5%), 소실 후
재발 2안(15.4%), 지속 4안(30.8%), 망막색소상피 파열이 2안(15.4%)이었다. 맥락막혈관신생 군은 66.7%(6/9), 진단이 모호한 군은
100% (4/4)에서 시력이 유지되거나 향상되었다.
결론: 큰 망막색소상피박리를 동반한 신생혈관 나이관련황반변성에서 복합치료는 시력유지 및 호전을 기대할 수 있는 선택적인 치료
방법이다. 추후 장기간의 관찰과 항 혈관내피성장인자 항체의 단일치료와 대조연구가 필요하다.

참고문헌 (Reference)

1 한정원, "큰 장액 망막색소상피박리가 동반된 맥락막신생혈관에 대한 광역학치료의 효과" 대한안과학회 45 (45): 79-86, 2004

2 Ferrara N, "Vascular endothelial growth factor. The trigger for neovascularization in the eye" 72 : 615-618, 1995

3 Adamis SP, "The role of vascular endothelial growth factor in ocular health and disease" 25 : 111-118, 2005

4 Coscas G, "The pretear characteristics of pigment epithelial detachments. A study of 40 eyes" 108 : 1687-1693, 1990

5 Oh H, "The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes" 40 : 1891-1898, 1999

6 Elman MJ, "The naturalhistory of serous retinal pigment epithelium detachment in patients with age-related macular degeneration" 93 : 224-230, 1986

7 Chang LK, "Tears of the retinal pigment epithelium: an old problem in a new era" 27 : 523-534, 2007

8 Freund KB, "Sequenced combined intravitreal triamcinolone and indocyanine green angiographyguided photodynamic therapy for retinal angiomatous proliferation" 124 : 487-492, 2006

9 Chan CK, "Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular agerelated macular degeneration" 27 : 541-551, 2007

10 Goldstein M, "Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD" 9 : 1315-1324, 2005

11 Gass JD, "Retinal pigment epithelial rip during krypton red laser photocoagulation" 98 : 700-706, 1984

12 Casswell AG, "Retinal pigment epithelial detachments in the elderly: classification and outcome" 69 : 397-403, 1985

13 Spaide RF, "Rationale for combination therapies for choroidal neovascularization" 141 : 149-156, 2006

14 Chang LK, "RPE tears after pegaptanib treatment in age-related macular degeneration" 27 : 857-863, 2007

15 Krzystolik MG, "Prevention of experimental choroidal neovascularization with intravitreal antivascular endothelial growth factor antibody fragment" 120 : 338-346, 2002

16 Pauleikhoff D, "Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications" 240 : 533-538, 2002

17 Pece A, "Photodynamic therapy with verteporfin for choroidal neovascularization associated with retinal pigment epithelial detachment in age-related macular degeneration" 27 : 342-348, 2007

18 "Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group" 117 : 1329-1345, 1999

19 Axer-Siegel R, "Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration" 122 : 453-459, 2004

20 Meredith TA, "Natural history of serous detachments of the retinal pigment epithelium" 88 : 643-651, 1979

21 Poliner LS, "Natural history of retinal pigment epithelial detachments in age-related macular degeneration" 93 : 543-550, 1986

22 Schmidt-Erfurth U, "Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration" 45 : 195-214, 2000

23 Smith BT, "Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration" 28 : 675-681, 2008

24 Chen E, "Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration" 27 : 445-450, 2007

25 Bom Aggio F, "Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration" 84 : 713-714, 2006

26 Ladas ID, "Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration" 27 : 891-896, 2007

27 Costa RA, "Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study)" 245 : 1273-1280, 2007

28 Frimpong-Boateng A, "Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD" 105 : 661-668, 2008

29 Schmidt-Erfurth U, "Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor" 44 : 4473-4480, 2003

30 Lim JI, "Indocyanine green angiography-guided photocoagulation of choroidal neovascularization associated with retinal pigment epithelial detachment" 123 : 524-532, 19997

31 Brancato R, "ICGA-guided laser photocoagulation of occult choroidal neovascularization in agerelated macular degeneration" 20 : 134-142, 2000

32 Dastgheib K, "Granulomatous reaction to Bruch’s membrane in age-related macular degeneration" 112 : 813-818, 1994

33 Ladas ID, "Efficacy of photodynamic therapy in the management of occult choroidal neovascularization associated with serous pigment epithelium detachment" 221 : 313-319, 2007

34 Ferrara N, "Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration" 26 : 859-870, 2006

35 Spaide RF, "Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization" 110 : 1517-1525, 2003

36 Dhalla MS, "Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration" 26 : 988-993, 2006

37 Chan WM, "Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularization in age related macular degeneration: a comparative study" 90 : 337-341, 2006

38 Ladewig MS, "Combined intravitreal bevacizumab and photodynamic therapy for neovascular agerelated macular degeneration" 246 : 17-25, 2008

39 Meyer CH, "Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularization secondary to age related macular degeneration" 90 : 1207-1208, 2006

40 Slakter JS, "A pilot study of indocyanine green videoangiography guided laser photocoagulation treatment of occult choroidal neovascularization" 112 : 465-472, 1994